Business
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
FEATURED STORIES
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.
Flagship Pioneering announced the launch of Sonata Therapeutics. The fledgling company was created by combining two Flagship companies, Inzen Therapeutics and Cygnal Therapeutics.
Applied Molecular Transport (AMT) provided a strategy update on Wednesday. Part of the update includes reducing its workforce by about 40% and funneling resources into its lead program.
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
The current president, CEO and board member, Keith Kendall, is departing Aquestive. He will be replaced by Daniel Barber, its current chief operating officer.
Hengrui Pharma is seeking to make medicines more available and affordable worldwide with the launch of Luzsana that opens up access to treatment for hundreds of illnesses.
ShouTi believes many targets addressed by biologic and peptide therapeutics can be reached by innovative, rationally-designed, best-in-class small molecules that don’t need refrigeration or injection.
Vertex Pharmaceuticals dedicated a new site in Boston’s Seaport. But the company seemed to say, “But wait! There’s more!” and announced it plans to build another facility in the area.
RQ Biotechnology has officially launched, with the financial backing of AstraZeneca. The move strategically increases the availability of monoclonal antibodies at a time of ever-increasing demand.